drugset / Trial / NCT04070313
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
Phase 2
Terminated
36 enrolled
TTY Biopharm
Chang Gung Memorial Hospital · collabNational Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collabTaipei Veterans General Hospital, Taiwan · collab
NaSingle-groupOpen-labelTreatment
Summary
To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer. * Primary Endpoint: Relapse-free survival (RFS) * Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
Timeline
- Start
- 2019-07-11
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
Outcome
Outcome not reported
Stopped: “Study treatment is to use TS-1 (mono-chemotherapy agent) in adjuvant setting for pancreatic cancer, which may be less clinical benefit compared to combination therapy according to current trend at investigators' discretion.”